Cancer is maintained by the activity of a rare population of self-renewing cancer stem cells (CSCs), which are resistant to conventional therapies. CSCs share several antigenic determinants with pluripotent stem cells (PSCs). We show here that PSCs, combined with a histone deacetylase inhibitor (HDACi), are able to elicit major anti-tumor responses in a model of highly aggressive breast cancer. This immunotherapy strategy was effective in preventing tumor establishment and efficiently targeted CSCs by inducing extensive modifications of the tumor microenvironment. The anti-tumor effect was correlated with a reduction in regulatory T and myeloid-derived suppressor cell populations and an increase in cytotoxic CD8+T cells within the tumor and the spleen along with a drastic reduction in metastatic dissemination and an improvement in the survival rate. These results demonstrate for the first time the possibility of using PSCs and HDACi as an allogeneic anticancer vaccine, in future universal immunotherapy strategies.

中文翻译：

---

具有抗转移潜力的药理修饰多能干细胞癌疫苗

癌症通过罕见的自我更新癌症干细胞（CSC）群体的活动来维持，这些癌症干细胞对常规疗法具有抵抗力。CSC与多能干细胞（PSC）共享几个抗原决定簇。我们在这里显示，PSC与组蛋白脱乙酰基酶抑制剂（HDACi）结合，能够在高度侵袭性乳腺癌模型中引发主要的抗肿瘤反应。这种免疫疗法通过诱导肿瘤微环境的广泛修饰，可有效预防肿瘤的形成并有效靶向CSC。该抗肿瘤作用与调节性T和髓样来源的抑制细胞群的减少以及肿瘤和脾脏中细胞毒性CD8 + T细胞的增加以及转移性扩散的大幅度减少和存活率的提高相关。这些结果首次证明了在未来的通用免疫治疗策略中将PSC和HDACi用作同种异体抗癌疫苗的可能性。